HRP20110196T1 - 3,5-disupstituirani fenil-piperidini kao modulatori dopamina neurotransmisije - Google Patents

3,5-disupstituirani fenil-piperidini kao modulatori dopamina neurotransmisije Download PDF

Info

Publication number
HRP20110196T1
HRP20110196T1 HR20110196T HRP20110196T HRP20110196T1 HR P20110196 T1 HRP20110196 T1 HR P20110196T1 HR 20110196 T HR20110196 T HR 20110196T HR P20110196 T HRP20110196 T HR P20110196T HR P20110196 T1 HRP20110196 T1 HR P20110196T1
Authority
HR
Croatia
Prior art keywords
disorders
pharmaceutical preparation
group
treatment
preparation according
Prior art date
Application number
HR20110196T
Other languages
English (en)
Inventor
Sonesson Clas
Original Assignee
Nsab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nsab filed Critical Nsab
Publication of HRP20110196T1 publication Critical patent/HRP20110196T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Spoj Formule 1, naznačen time, što je: R izabran iz grupe koja sadrži C1-C3 alkile i alil; i njegove farmaceutski prihvatljive soli. Patent sadrži još 18 patentnih zahtjeva.

Claims (19)

1. Spoj Formule 1, naznačen time, što je: [image] R izabran iz grupe koja sadrži C1-C3 alkile i alil; i njegove farmaceutski prihvatljive soli.
2. Spoj prema zahtjevu 1, naznačen time, što je R izabran iz grupe koja sadrži n-propil i etil.
3. Spoj prema zahtjevu 1, naznačen time, što je 1-etil-4-[3-fluoro-5-(metilsulfonil)fenil]piperidin; ili njegova farmaceutski prihvatljiva sol.
4. Spoj prema zahtjevu 1, naznačen time, što je 1-etil-4-[3-fluoro-5-(metilsulfonil)fenil]piperidin sol hidroklorične kiseline.
5. Spoj prema zahtjevu 1, naznačen time, što je 4-[3-fluoro-5-(metilsulfonil)fenil]-1-propilpiperidin; ili njegova farmaceutski prihvatljiva sol.
6. Spoj prema zahtjevu 1, naznačen time, što je 4-[3-fluoro-5-(metilsulfonil)fenil]-1-propilpiperidin sol hidroklorične kiseline
7. Spoj prema zahtjevu 1, naznačen time, što je 1-alil-4-[3-fluoro-5-(metilsulfonil)fenil]piperidin; ili njegova farmaceutski prihvatljiva sol.
8. Farmaceutski pripravak, naznačen time što sadrži spoj prema bilo kojem zahtjevu 1-7 i jedan ili više farmaceutski prihvatljiv nosač ili razrjeđivač.
9. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje poremećaja središnjeg živčanog sustava.
10. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje poremećaja kretanja odabranih iz skupine koja se sastoji od Parkinsonove bolesti, parkinsonizma, diskinezije (uključujući L-DOPA induciran diskinezijom), distonije, tikova, drhtanja i Huntingtonove bolesti.
11. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje stanja odabranih iz skupine koja se sastoji od jatrogene i nejatrogene psihoze i halucinacija.
12. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje stanja odabranih iz skupine koja se sastoji od shizofrenije i shizofreničnih poremećaja i bipolarnog poremećaja.
13. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje stanja odabranih iz skupine koja se sastoji od poremećaja raspoloženja i anksioznosti, depresije i opsesivno-kompulzivnog poremećaja.
14. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje neuro-razvojnih poremećaja odabranih iz skupine koja se sastoji od poremećaja autističnog spektra, ADHD, cerebralne paralize, Gilles de la Tourette bolesti i neurodegenerativnih poremećaja odabranih iz skupine koja se sastoji od demencije i dobnog kognitivnog oštećenja.
15. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za liječenje stanja odabranih iz skupine koja se sastoji od poremećaja spavanja, seksualnih poremećaja, poremećaja u prehrani, gojaznosti, glavobolja i drugih bolova u uvjetima karakteriziranim povećanjem mišićnog tonusa.
16. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za poboljšanje motoričkih funkcija, kognitivnih funkcija i srodnih emocionalnih poremećaja, a nakon ozljede mozga induciran traumatskim, upalnim, infektivnim, neoplastičnim, vaskularnim, hipoksičkim ili metaboličkim uzrocima ili ozljeda mozga inducirana toksičnim reakcijama na egzogenim kemikalijama, pri čemu su egzogene kemikalije odabrane iz skupine koja se sastoji od zloupotrebe supstance, farmaceutskih spojeva, toksina okoliša.
17. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je liječenje poremećaja srodnih zloupotrebi supstance.
18. Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je liječenje Alzheimerove bolesti ili srodnih poremećaja demencije.
19. Spoj prema bilo kojem zahtjevu 1-7, ili njegova farmaceutski prihvatljiva sol naznačen time, što je za uporabu kao lijek.
HR20110196T 2005-10-13 2011-03-16 3,5-disupstituirani fenil-piperidini kao modulatori dopamina neurotransmisije HRP20110196T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0502254A SE529246C2 (sv) 2005-10-13 2005-10-13 Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
PCT/EP2006/009866 WO2007042295A1 (en) 2005-10-13 2006-10-12 3, 5-disubstituted phenyl-piperidines as mdulators of dopamine? neurotransmission

Publications (1)

Publication Number Publication Date
HRP20110196T1 true HRP20110196T1 (hr) 2011-05-31

Family

ID=37467527

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110196T HRP20110196T1 (hr) 2005-10-13 2011-03-16 3,5-disupstituirani fenil-piperidini kao modulatori dopamina neurotransmisije

Country Status (24)

Country Link
US (1) US8501777B2 (hr)
EP (1) EP1948606B1 (hr)
JP (1) JP4857346B2 (hr)
KR (1) KR20080046720A (hr)
CN (1) CN101273014B (hr)
AT (1) ATE494277T1 (hr)
AU (1) AU2006301432B2 (hr)
BR (1) BRPI0617355A2 (hr)
CA (1) CA2625663A1 (hr)
DE (1) DE602006019470D1 (hr)
DK (1) DK1948606T3 (hr)
ES (1) ES2358537T3 (hr)
HK (1) HK1125097A1 (hr)
HR (1) HRP20110196T1 (hr)
IL (1) IL189298A0 (hr)
MY (1) MY143241A (hr)
NO (1) NO20082174L (hr)
NZ (1) NZ566015A (hr)
PL (1) PL1948606T3 (hr)
RU (1) RU2418787C2 (hr)
SE (1) SE529246C2 (hr)
UA (1) UA93380C2 (hr)
WO (1) WO2007042295A1 (hr)
ZA (1) ZA200802238B (hr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
DE602005021641D1 (de) 2004-06-08 2010-07-15 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin-neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
CN101056854B (zh) 2004-10-13 2013-06-05 Nsab神经研究瑞典公司分公司 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法
RU2470013C2 (ru) 2007-04-12 2012-12-20 НСАБ, Филиаль ау НьюроСёрч Свиден АБ, Сверийе N-оксидные и/или ди-n-оксидные производные стабилизаторов/модуляторов рецепторов дофамина, проявляющие улучшенные профили сердечно-сосудистых побочных эффектов
WO2009133107A1 (en) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
MX2010011498A (es) * 2008-04-29 2010-11-12 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.
JP2011519839A (ja) * 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH 併用療法のための医薬組成物
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3503890A4 (en) * 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIA
WO2019050775A1 (en) * 2017-09-08 2019-03-14 Teva Pharmaceuticals International Gmbh PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB850662A (en) 1956-10-22 1960-10-05 Parke Davis & Co Substituted piperazines and processes for their production
BE662455A (hr) 1964-04-14
FR1459013A (fr) 1964-08-05 1966-04-29 Allen & Hanburys Ltd Procédé de préparation de dérivés de la 4-phényl-pipéridine
GB1060160A (en) 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
ZA7546B (en) 1974-01-21 1976-08-25 Parke Davis & Co New antibacterial amide compounds and methods for their production
GB1560271A (en) 1977-01-14 1980-02-06 Joullie International Sa Therapeutically useful m-trifluoromethylphenylpiperazine derivatives
US4202898A (en) 1978-06-05 1980-05-13 Synthelabo Method of treating anxiety and depression
FR2459797A2 (fr) 1978-08-01 1981-01-16 Synthelabo Derives de phenyl-1 piperazine et leur application en therapeutique
US4333942A (en) 1979-08-03 1982-06-08 Byk Gulden Lomberg Chemische Fabrik Gmbh Anti-depressant and analgesic 4-phenoxypiperidines
US4518712A (en) 1980-06-30 1985-05-21 Taiho Pharmaceutical Company Limited Piperazine derivative and analgesic composition containing the same
GB2083476B (en) 1980-09-12 1984-02-08 Wyeth John & Brother Ltd Heterocyclic compounds
FR2501506A1 (fr) 1981-03-11 1982-09-17 Sanofi Sa Compositions pharmaceutiques a action anorexigene contenant des derives de la tetrahydropyridine
US4415736A (en) 1981-12-28 1983-11-15 E. I. Du Pont De Nemours & Co. Certain tetrahydropyridine intermediates
ATE50987T1 (de) 1982-05-10 1990-03-15 Takeda Chemical Industries Ltd Dihydropyridinderivate, deren herstellung und verwendung.
US4504660A (en) 1982-07-06 1985-03-12 American Home Products Corporation Process for the production of 2,6-diaminobenzonitrile derivatives
HU198454B (en) 1987-12-14 1989-10-30 Richter Gedeon Vegyeszet Process for production of new derivatives of tetrahydrospiridin and medical compositions containing these compounds
FR2639226B1 (fr) 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
EP0641320B1 (en) 1991-04-17 2001-05-30 PHARMACIA & UPJOHN COMPANY Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists
AU676993B2 (en) 1991-06-27 1997-04-10 Virginia Commonwealth University Sigma receptor ligands and the use thereof
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119932D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
ATE204262T1 (de) 1991-09-18 2001-09-15 Glaxo Group Ltd Benzanilidderivate als 5-ht1d-antagonisten
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
EP0659743A1 (en) 1993-12-27 1995-06-28 Hoechst Aktiengesellschaft Piperidine derivatives as inhibitors of platelet aggregation and their preparation
CA2144669A1 (en) 1994-03-29 1995-09-30 Kozo Akasaka Biphenyl derivatives
ZA954688B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H Serotonin 5-HT1A and dopamin D2 receptor ligands
WO1997003986A1 (fr) 1995-07-19 1997-02-06 Yoshitomi Pharmaceutical Industries, Ltd. Composes fusionnes de triazole
US5892041A (en) 1996-08-12 1999-04-06 Neurogen Corporation Fused indolecarboxamides: dopamine receptor subtype specific ligands
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
AU3108097A (en) 1997-06-10 1998-12-30 Synthon B.V. 4-phenylpiperidine compounds
US6232326B1 (en) 1998-07-14 2001-05-15 Jodi A. Nelson Treatment for schizophrenia and other dopamine system dysfunctions
JP2000086603A (ja) 1998-07-15 2000-03-28 Yoshitomi Pharmaceut Ind Ltd 桂皮酸アミド誘導体および3―フェニルプロピオン酸アミド誘導体
NZ515543A (en) 1999-06-22 2003-11-28 Neurosearch As Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
AU2001280599A1 (en) 2000-07-15 2002-01-30 Smith Kline Beecham Corporation Compounds and methods
US7186715B2 (en) 2001-01-08 2007-03-06 Eli Lilly And Company Piperazine- and piperidine-derivatives as melanocortin receptor agonists
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
DE602005021641D1 (de) 2004-06-08 2010-07-15 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin-neurotransmission
EP1768958B1 (en) 2004-06-08 2009-11-18 NSAB, Filial af NeuroSearch Sweden AB, Sverige New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
EP1796669B1 (en) 2004-10-01 2010-09-22 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
MX2007004216A (es) * 2004-10-13 2007-10-10 Neurosearch Sweden Ab Proceso para la sintesis de 4-(3-sulfonil)-piperidinas.
US20080318999A1 (en) 2005-08-05 2008-12-25 Methvin Isaac Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators
US20080269286A1 (en) 2005-12-07 2008-10-30 Clas Sonesson Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission

Also Published As

Publication number Publication date
RU2418787C2 (ru) 2011-05-20
SE529246C2 (sv) 2007-06-12
HK1125097A1 (en) 2009-07-31
ES2358537T3 (es) 2011-05-11
CA2625663A1 (en) 2007-04-19
JP4857346B2 (ja) 2012-01-18
AU2006301432B2 (en) 2011-12-15
MY143241A (en) 2011-04-15
ATE494277T1 (de) 2011-01-15
DE602006019470D1 (de) 2011-02-17
PL1948606T3 (pl) 2011-08-31
CN101273014A (zh) 2008-09-24
EP1948606A1 (en) 2008-07-30
NZ566015A (en) 2010-11-26
UA93380C2 (en) 2011-02-10
RU2008108618A (ru) 2009-11-20
WO2007042295A1 (en) 2007-04-19
AU2006301432A1 (en) 2007-04-19
JP2009511525A (ja) 2009-03-19
IL189298A0 (en) 2008-06-05
NO20082174L (no) 2008-07-11
ZA200802238B (en) 2009-10-28
CN101273014B (zh) 2011-01-12
KR20080046720A (ko) 2008-05-27
SE0502254L (sv) 2007-04-14
US8501777B2 (en) 2013-08-06
US20080234321A1 (en) 2008-09-25
EP1948606B1 (en) 2011-01-05
DK1948606T3 (da) 2011-04-04
BRPI0617355A2 (pt) 2011-07-26

Similar Documents

Publication Publication Date Title
HRP20110196T1 (hr) 3,5-disupstituirani fenil-piperidini kao modulatori dopamina neurotransmisije
JP2009511525A5 (hr)
BR112015025140A2 (pt) 2-fenilimidazo[1,2-a]pirimidinas como agentes de imagem
JP2010523651A5 (hr)
BR9500996A (pt) Derivado de difenila,agente terapêutico,processo para a preparação de um derivado de difenila,derivado de fenilpiperazina,composição farmacológica e métodos para fazer um medicamento e para tratar ou melhorar uma doença
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
JP2015523406A5 (hr)
EA201001181A1 (ru) ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[e ИЛИ d]ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
JP2020502092A5 (hr)
AR045659A1 (es) Derivados de tiazolopiridina
EP2604602A4 (en) HETEROARYLPYRAZOLDERIVAT
BRPI0408591A (pt) derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda
MX2015002398A (es) Benzimidazoles como agentes activos del sistema nervioso central.
BRPI0409739A (pt) composto, composição farmacêutica, uso de composto, e, método para o tratamento de uma doença ou de um distúrbio
AR048348A1 (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos
AR081908A1 (es) N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas
AR054785A1 (es) Compuesto que comprende pirazolo (1,5-a) pirimidinas halogenadas, procedimiento para prepararlo uso de dicho compuesto composicion farmaceutica que lo comprende, procedimiento para preparar sus intermedios y compuesto intermedio
ATE367163T1 (de) 4-(sulfanylpyrimidin-4-ylmethyl)morpholin- derivate und verwandte verbindungen als gaba- rezeptorliganden zur behandlung von angst, depression und epilepsie
CL2011000520A1 (es) Compuestos derivados de piperazina; uso para preparar un medicamento util para tratar la enfermedad de alzheimaer, un trastorno neurodegenerativo y amiloidosis; metodo de preparacion de compuestos.
RU2020127537A (ru) Соединения, которые модулируют функцию ampa-рецептора
JP2012509860A5 (hr)
FI3541784T3 (fi) Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina
CN101400407A (zh) 具有中枢神经系统活性的升托品烷
TH127359A (th) อนุพันธ์ 1,2,4-ไตรอะโซโล[4,3-a]ไพริดีนและการใช้มันในฐานะโพสิทิฟ อัลโลสเตริก มอดูเลเตอร์ ของหน่วยรับความรู้สึก MGLUR2